Significance of p2x7 receptor variants to human health and disease

Recent Patents on DNA and Gene Sequences

Volumn 5, Issue 1, 2011, Pages 41-54

  Sluyter, Ronald ^a,b   Stokes, Leanne ^c  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b ILLAWARRA HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Extracellular atp; P2rx7; Patent; Purinergic receptor; Single nucleotide polymorphism; Splice isoform

Indexed keywords

ALANINE; GLUTAMINE; PURINERGIC P2X7 RECEPTOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANXIETY; ARTICLE; BIPOLAR DISORDER; BLOOD PRESSURE MONITORING; BREAST CANCER; CELL TYPE; CHRONIC LYMPHATIC LEUKEMIA; CROHN DISEASE; EXON; FRACTURE; GENETIC VARIABILITY; GEOMETRY; HEART FAILURE; HIP; HUMAN; LUMBAR SPINE; MAJOR DEPRESSION; MULTIPLE MYELOMA; NASOPHARYNX CARCINOMA; OSTEOLYSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RNA SPLICING; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROID PAPILLARY CARCINOMA; TOXOPLASMOSIS; TUBERCULOSIS;

EID: 79952756152     PISSN: 18722156     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221511794839219     Document Type: Article

References (168)

1. Burnstock G. Purine and pyrimidine receptors. Cell Mol Life Sci 2007; 64: 1471-1483.
2. Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochim Biophys Acta 2008; 1783: 673-694.
3. Jarvis MF, Khakh BS. ATP-gated P2X cation channels. Neuro- pharmacology 2009; 56: 208-215.
4. Surprenant A, North RA. Signaling at purinergic P2X receptors. Annu Rev Physiol 2009; 71: 333-359.
5. Hughes JP, Hatcher JP, Chessell IP. The role of P2X7 in pain and inflammation. Purinergic Signal 2007; 3: 163-169.
6. Di Virgilio F, Ferrari D, Adinolfi E. P2X7: a growth-promoting receptor-implication for cancer. Purinergic Signal 2009; 5: 251-256.
7. Coutinho-Silva R, Correa G, Sater AA, Ojcius DM. The P2X7 receptor and intracellular pathogens: a continuing struggle. Purinergic Signal 2009; 5: 197-204.
8. Burnstock G, Knight GE. Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol 2004; 240: 31-304.
9. Friedle SA, Curet MA, Watters JJ. Recent patents on novel P2X7 receptor antagonists and their potential for reducing central nervous system inflammation. Recent Pat CNS Drug Discov 2010; 5: 35-45.
10. Guile SD, Alcaraz L, Birkinshaw TN, et al. Antagonists of the P2X7 receptor. From lead identification to drug development. J Med Chem 2009; 52: 3123-3141.
11. Nicke A. Homotrimeric complexes are the dominant assembly state of native P2X7 subunits. Biochem Biophys Res Commun 2008; 377: 803-808.
12. Rassendren F, Buell GN, Virginio C, Collo G, North RA, Sur-prenant A. The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. J Biol Chem 1997; 272: 5482-5486.
13. Surprenant A, Rassendren F, Kawashima E, North RA, Buell G. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 1996; 272: 735-738.
14. Roger S, Mei ZZ, Baldwin JM, et al. Single nucleotide polymor-phisms that were identified in affective mood disorders affect ATP- activated P2X7 receptor functions. J Psychiatr Res 2010; 44: 347-355.
15. Kawate T, Michel JC, Birdsong WT, Gouaux E. Crystal structure of the ATP-gated P2X4 ion channel in the closed state. Nature 2009; 460: 592-598.
16. Guo C, Masin M, Qureshi OS, Murrell-Lagnado RD. Evidence for functional P2X4/P2X7 heteromeric receptors. Mol Pharmacol 2007; 72: 1447-1456.
17. Torres GE, Egan TM, Voigt MM. Hetero-oligomeric assembly of P2X receptor subunits. J Biol Chem 1999; 274: 6653-6659.
18. Georgiou JD, Skarratt KK, Fuller SJ, et al. Human epidermal and monocyte-derived Langerhans cells express functional P2X7 receptors. J Invest Dermatol 2005; 125: 482-490.
19. Gu BJ, Zhang WY, Bendall LJ, Chessell IP, Buell GN, Wiley JS. Expression of P2X7 purinoceptors on human lymphocytes and monocytes: evidence for nonfunctional P2X7 receptors. Am J Physiol Cell Physiol 2000; 279: C1189-C97.
20. Sluyter R, Wiley JS. Extracellular adenosine 5'-triphosphate induces a loss of CD23 from human dendritic cells via activation of P2X7 receptors. Int Immunol 2002; 14: 1415-1421.
21. Stevenson RO, Taylor RM, Wiley JS, Sluyter R. The P2X7 receptor mediates the uptake of organic cations in canine erythrocytes and mononuclear leukocytes: comparison to equivalent human cell types. Purinergic Signal 2009; 5: 385-394.
22. Wareham K, Vial C, Wykes RC, Bradding P, Seward EP. Func-tional evidence for the expression of P2X1, P2X4 and P2X7 recep-tors in human lung mast cells. Br J Pharmacol 2009; 157: 1215-1224.
23. Chakfe Y, Seguin R, Antel JP, et al. ADP and AMP induce inter-leukin-1beta release from microglial cells through activation of ATP-primed P2X7 receptor channels. J Neurosci 2002; 22: 3061-3069.
24. Hoebertz A, Townsend-Nicholson A, Glass R, Burnstock G, Arnett TR. Expression of P2 receptors in bone and cultured bone cells. Bone 2000; 27: 503-510.
25. Ferrari D, Idzko M, Dichmann S, et al. P2 purinergic receptors of human eosinophils: characterization and coupling to oxygen radical production. FEBS Lett 2000; 486: 217-224.
26. Martel-Gallegos G, Rosales-Saavedra MT, Reyes JP, et al. Human neutrophils do not express purinergic P2X7 receptors. Purinergic Signal 2010; 6: 297-306.
27. Vaughan KR, Stokes L, Prince LR, et al. Inhibition of neutrophil apoptosis by ATP is mediated by the P2Y11 receptor. J Immunol 2007; 179: 8544-8553.
28. Gartland A, Hipskind RA, Gallagher JA, Bowler WB. Expression of a P2X7 receptor by a subpopulation of human osteoblasts. J Bone Miner Res 2001; 16: 846-856.
29. Solini A, Chiozzi P, Morelli A, Fellin R, Di Virgilio F. Human primary fibroblasts in vitro express a purinergic P2X7 receptor coupled to ion fluxes, microvesicle formation and IL-6 release. J Cell Sci 1999; 112: 297-305.
30. Wilson HL, Varcoe RW, Stokes L, et al. P2X receptor characteri-zation and IL-1/IL-1Ra release from human endothelial cells. Br J Pharmacol 2007; 151: 115-127.
31. Garcia-Marcos M, Pochet S, Marino A, Dehaye JP. P2X7 and phospholipid signalling: the search of the missing link in epithelial cells. Cell Signal 2006; 18: 2098-2104.
32. Gorodeski GI. P2X7-mediated chemoprevention of epithelial can-cers. Expert Opin Ther Targets 2009; 13: 1313-1332.
33. Anderson CM, Nedergaard M. Emerging challenges of assigning P2X7 receptor function and immunoreactivity in neurons. Trends Neurosci 2006; 29: 257-262.
34. Duan S, Neary JT. P2X7 receptors: properties and relevance to CNS function. Glia 2006; 54: 738-746.
35. Deli T, Csernoch L. Extracellular ATP and cancer -an overview with special reference to P2 purinergic receptors. Pathol Oncol Res 2008; 14: 219-231.
36. White N, Burnstock G. P2 receptors and cancer. Trends Pharmacol Sci 2006; 27: 211-217.
37. Di Virgilio F. Liaisons dangereuses: P2X7 and the inflammasome. Trends Pharmacol Sci 2007; 28: 465-472.
38. Farrell AW, Gadeock S, Pupovac A, et al. P2X7 receptor activation induces cell death and CD23 shedding in human RPMI 8226 multiple myeloma cells. Biochim Biophys Acta 2010; 1800: 1173-1182.
39. Gu B, Bendall LJ, Wiley JS. Adenosine triphosphate-induced shedding of CD23 and L-selectin (CD62L) from lymphocytes is mediated by the same receptor but different metalloproteases. Blood 1998; 92: 946-951.
40. Gu BJ, Wiley JS. Rapid ATP-induced release of matrix metallopro-teinase 9 is mediated by the P2X7 receptor. Blood 2006; 107: 4946-4953.
41. Jamieson GP, Snook MB, Thurlow PJ, Wiley JS. Extracellular ATP causes of loss of L-selectin from human lymphocytes via occupancy of P2Z purinocepters. J Cell Physiol 1996; 166: 637-642.
42. Lopez-Castejon G, Theaker J, Pelegrin P, Clifton AD, Braddock M, Surprenant A. P2X7 receptor-mediated release of cathepsins from macrophages is a cytokine-independent mechanism potentially in-volved in joint diseases. J Immunol 2010; 185: 2611-2619.
43. Sengstake S, Boneberg EM, Illges H. CD21 and CD62L shedding are both inducible via P2X7Rs. Int Immunol 2006; 18: 1171-1178.
44. Qu Y, Dubyak GR. P2X7 receptors regulate multiple types of membrane trafficking responses and non-classical secretion path-ways. Purinergic Signal 2009; 5: 163-173.
45. Hewinson J, Mackenzie AB. P2X7 receptor-mediated reactive oxygen and nitrogen species formation: from receptor to generators. Biochem Soc Trans 2007; 35: 1168-1170.
46. Buell GN, Talabot F, Gos A, et al. Gene structure and chromoso-mal localization of the human P2X7 receptor. Receptors Channels 1998; 5: 347-354.
47. Kato T. Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci 2007; 61: 3-19.
48. Shen N, Tsao BP. Current advances in the human lupus genetics. Curr Rheumatol Rep 2004; 6: 391-398.
49. Li CM, Campbell SJ, Kumararatne DS, et al. Association of a polymorphism in the P2X7 gene with tuberculosis in a Gambian population. J Infect Dis 2002; 186: 1458-1462.
50. Zhou L, Luo L, Qi X, Li X, Gorodeski GI. Regulation of P2X7 gene transcription. Purinergic Signal 2009; 5: 409-426.
51. Zhou L, Qi X, Potashkin JA, Abdul-Karim FW, Gorodeski GI. MicroRNAs miR-186 and miR-150 down-regulate expression of the pro-apoptotic purinergic P2X7 receptor by activation of insta-bility sites at the 3'-untranslated region of the gene that decrease steady-state levels of the transcript. J Biol Chem 2008; 283: 28274-28286.
52. Rahman OA, Sasvari-Szekely M, Szekely A, Faludi G, Guttman A, Nemoda Z. Analysis of a polymorphic microRNA target site in the purinergic receptor P2RX7 gene. Electrophoresis 2010; 31: 1790-1795.
53. Cheewatrakoolpong B, Gilchrest H, Anthes JC, Greenfeder S. Identification and characterization of splice variants of the human P2X7 ATP channel. Biochem Biophys Res Commun 2005; 332: 17-27.
54. Adinolfi E, Cirillo M, Woltersdorf R, et al. Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor. FASEB J 2010; 24: 3393-3404.
55. Feng Y-H, Li X, Wang L, Zhou L, Gorodeski GI. A truncated P2X7 receptor variant (P2X7-j) endogenously expressed in cervical cancer cells antagonizes the full-length P2X7 receptor through het-ero-oligomerization. J Biol Chem 2006; 281: 17228-17237.
56. Skarratt KK, Fuller SJ, Sluyter R, Dao-Ung LP, Gu BJ, Wiley JS. A 5' intronic splice site polymorphism leads to a null allele of the P2X7 gene in 1% to 2% of the Caucasian population. FEBS Lett 2005; 579: 2675-2678.
57. Nicke A, Kuan YH, Masin M, et al. A functional P2X7 splice variant with an alternative transmembrane domain 1 escapes gene inactivation in P2X7 knock-out mice. J Biol Chem 2009; 284: 25813-25822.
58. Sun C, Chu J, Singh S, Salter R. Identification and characterization of a novel variant of the human P2X7 receptor resulting in gain of function. Purinergic Signal 2010; 6: 31-45.
59. Gu BJ, Zhang WY, Worthington RA, et al. A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J Biol Chem 2001; 276: 11135-11142.
60. Fernando SL, Saunders BM, Sluyter R, Skarratt KK, Wiley JS, Britton WJ. Gene dosage determines the negative effects of poly-morphic alleles of the P2X7 receptor on adenosine triphosphate-mediated killing of mycobacteria by human macrophages. J Infect Dis 2005; 192: 149-155.
61. Lees MP, Fuller SJ, McLeod R, et al. P2X7 receptor-mediated killing of an intracellular parasite, Toxoplasma gondii, by human and murine macrophages. J Immunol 2010; 184: 7040-7046.
62. Shemon AN, Sluyter R, Fernando SL, et al. A Thr357 to Ser poly-morphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and function impairs ATP-induced mycobacterial killing by macrophages. J Biol Chem 2006; 281: 2079-2086.
63. Stokes L, Fuller SJ, Sluyter R, Skarratt KK, Gu BJ, Wiley JS. Two haplotypes of the P2X7 receptor containing the Ala-348 to Thr polymorphism exhibit gain-of-function effect and enhanced inter-leukin-1 secretion. FASEB J 2010; 24: 2916-2927.
64. 496Ala polymorphism of human P2X7 receptor does not affect its electrophysiological phenotype. Am J Physiol Cell Physiol 2003; 284: C749-C56.
65. Sluyter R, Stokes L, Fuller SJ, Skarratt KK, Gu BJ, Wiley JS. Functional significance of P2RX7 polymorphisms associated with affective mood disorders. J Psychiatr Res 2010; 44: 1116-1117.
66. Cabrini G, Falzoni S, Forchap SL, et al. A His-155 to Tyr poly-morphism confers gain-of-function to the human P2X7 receptor of human leukemic lymphocytes. J Immunol 2005; 175: 82-89.
67. 307 to Gln polymor-phism within the ATP binding site causes loss of function of the human P2X7 receptor. J Biol Chem 2004; 279: 31287-31295.
68. Roberts JA, Vial C, Digby HR, et al. Molecular properties of P2X receptors. Pflugers Arch - Eur J Physiol 2006; 452: 486-500.
69. Wiley JS, Dao-Ung LP, Li C, et al. An Ile-568 to Asn polymor-phism prevents normal trafficking and function of the human P2X7 receptor. J Biol Chem 2003; 278: 17108-17113.
70. Xiao J, Sun L, Yan H, et al. Metaanalysis of P2X7 gene polymor-phisms and tuberculosis susceptibility. FEMS Immunol Med Mi-crobiol 2010; 60: 165-170.
71. Fernando SL, Saunders BM, Sluyter R, et al. A polymorphism in the P2X7 gene increases susceptibility to extrapulmonary tuberculosis. Am J Respir Crit Care Med 2007; 175: 360-366.
72. Saunders BM, Fernando SL, Sluyter R, Britton WJ, Wiley JS. A loss-of-function polymorphism in the human P2X7 receptor abol-ishes ATP mediated killing of mycobacteria. J Immunol 2003; in press:
73. 496 to Ala polymorphism in the P2X7 receptor impairs ATP-induced IL-1 release from human monocytes. J Immunol 2004; 172: 3399-3405.
74. Ghiringhelli F, Apetoh L, Tesniere A, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1 -dependent adaptive immunity against tumors. Nat Med 2009; 15: 1170-1178.
75. Thunberg U, Tobin G, Johnson A, et al. Polymorphism in the P2X7 receptor gene and survival in chronic lymphocytic leukaemia. Lancet 2002; 360: 1935-1939.
76. Wiley JS, Dao-Ung LP, Gu BJ, et al. A loss-of-function polymor-phic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study. Lancet 2002; 359: 1114-1119.
77. Nuckel H, Frey UH, Durig J, Duhrsen U, Siffert W. 1513A/C polymorphism in the P2X7 receptor gene in chronic lymphocytic leukemia: Absence of correlation with clinical outcome. Eur J Haematol 2004; 72: 259-263.
78. Sellick GS, Rudd M, Eve P, et al. The P2X7 receptor gene A1513C polymorphism does not contribute to risk of familial or sporadic chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev 2004; 13: 1065-1067.
79. Starczynski J, Pepper C, Pratt G, et al. The P2X7 receptor gene polymorphism 1513 A>C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemia. Br J Haematol 2003; 123: 66-71.
80. Zhang LY, Ibbotson RE, Orchard JA, et al. P2X7 polymorphism and chronic lymphocytic leukaemia: Lack of correlation with incidence, survival and abnormalities of chromosome 12. Leukemia 2003; 17: 2097-2100.
81. Barden N, Harvey M, Gagne B, et al. Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24.31 region points to P2RX7 as a susceptibility gene to bipolar affective disor-der. Am J Med Genet B Neuropsychiatr Genet 2006; 141: 374-382.
82. Hejjas K, Szekely A, Domotor E, et al. Association between depression and the Gln460Arg polymorphism of P2RX7 gene: A dimensional approach. Am J Med Genet B Neuropsychiatr Genet 2009; 150: 295-299.
83. Lucae S, Salyakina D, Barden N, et al. P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum Mol Genet 2006; 15: 2438-2445.
84. McQuillin A, Bass NJ, Choudhury K, et al. Case-control studies show that a non-conservative amino-acid change from a glutamine to arginine in the P2RX7 purinergic receptor protein is associated with both bipolar- and unipolar-affective disorders. Mol Psychiatry 2009; 14: 614-620.
85. Nagy G, Ronai Z, Somogyi A, et al. P2RX7 Gln460Arg polymor-phism is associated with depression among diabetic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1884-1888.
86. Green EK, Grozeva D, Raybould R, et al. P2RX7: A bipolar and unipolar disorder candidate susceptibility gene? Am J Med Genet B Neuropsychiatr Genet 2009; 150: 1063-1069.
87. Grigoroiu-Serbanescu M, Herms S, Muhleisen TW, et al. Variation in P2RX7 candidate gene (rs2230912) is not associated with bipo-lar I disorder and unipolar major depression in four European sam-ples. Am J Med Genet B Neuropsychiatr Genet 2009; 150: 1017-1021.
88. Lavebratt C, Aberg E, Sjoholm LK, Forsell Y. Variations in FKBP5 and BDNF genes are suggestively associated with depression in a Swedish population-based cohort. J Affect Disord 2010; 125: 249-255.
89. Al-Shukaili A, Al-Kaabi J, Hassan B. A comparative study of interleukin-1beta production and p2x7 expression after ATP stimulation by peripheral blood mononuclear cells isolated from rheuma-toid arthritis patients and normal healthy controls. Inflammation 2008; 31: 84-90.
90. Labasi JM, Petrushova N, Donovan C, et al. Absence of the P2X7 receptor alters leukcoyte function and attenuates an inflammatory response. J Immunol 2002; 168: 6436-6445.
91. Ke HZ, Qi H, Weidema AF, et al. Deletion of the P2X7 nucleotide receptor reveals its regulatory roles in bone formation and resorption. Mol Endocrinol 2003; 17: 1356-1367.
92. Yiangou Y, Facer P, Durrenberger P, et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 2006; 6: 12.
93. Sharp AJ, Polak PE, Simonini V, et al. P2x7 deficiency suppresses development of experimental autoimmune encephalomyelitis. J Neuroinflammation 2008; 5: 33.
94. Chen L, Brosnan CF. Exacerbation of experimental autoimmune encephalomyelitis in P2X7R-/- mice: evidence for loss of apoptotic activity in lymphocytes. J Immunol 2006; 176: 3115-3126.
95. Barden N, Sillaber I, Paez-Pereda M. Means and methods for diag-nosing and treating affective disorders. US7767398, 2010.
96. Barden N, Sillaber I, Paez-Pereda M. Means and methods for diag-nosing and treating affective disorders. WO2004092384, 2004.
97. Apetoh L, Tesniere A, Ghiringhelli F, Zitvogel L, Kroemer G. Use of P2X7 pathway for assessing the sensitivity of a subject to a cancer treatment. WO2010061246, 2010.
98. Martins I, Tesniere A, Kepp O, et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle 2009; 8: 3723-3728.
99. Ohshima Y, Tsukimoto M, Takenouchi T, et al. -Irradiation in-duces P2X7 receptor-dependent ATP release from B16 melanoma cells. Biochim Biophys Acta 2010; 1800: 40-46.
100. Diatchenko L, Maixner W. Identification of genetic polymorphic variants associated with somatosensory disorders and methods of using the same. US20090253585, 2009.
101. Chessell IP, Hatcher JP, Bountra C, et al. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 2005; 114: 386-396.
102. Donnelly-Roberts DL, Jarvis MF. Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor func-tion and indicates a role in chronic pain states. Br J Pharmacol 2007; 151: 571-579.
103. Honore P, Donnelly-Roberts D, Namovic MT, et al. A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino)methyl]amino}-2,2- dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neu-ropathic pain in the rat. J Pharmacol Exp Ther 2006; 319: 1376-1385.
104. Nelson DW, Gregg RJ, Kort ME, et al. Structure-activity relation-ship studies on a series of novel, substituted 1-benzyl-5- phenyltetrazole P2X7 antagonists. J Med Chem 2006; 49: 3659-3666.
105. Keith T, Little RD, Van Eerdewegh P, et al. Nucleotide and amino acid sequences relating to respiratory diseases and obesity. US7205146, 2007.
106. Olsson PG, Hulthe J, McPheat W, Eriksson POG. Polymorphisms and haplotypes in P2X7 gene and their use in determining suscepti-bility for atherosclerosis-mediated diseases. WO2006136791, 2006.
107. Morten JE. Polymorphisms in the human P2X7 gene. EP1741722, 2007.
108. Jursik C, Sluyter R, Georgiou JG, Fuller SJ, Wiley JS, Gu BJ. A quantitative method for routine measurement of cell surface P2X7 receptor function in leucocyte subsets by two-colour time-resolved flow cytometry. J Immunol Methods 2007; 325: 67-77.
109. Korpi-Steiner NL, Sheerar D, Puffer EB, et al. Standardized method to minimize variability in a functional P2X7 flow cytometric assay for a multi-center clinical trial. Cytometry B Clin Cytom 2008; 74: 319-29.
110. Denlinger LC, Hogan KJ, Bertics PJ, Schell K. White blood cell functional assay. US7560243, 2009.
111. Denlinger LC, Hogan KJ, Bertics PJ, Schell K. Functional genomic pore assay for mixed cell populations. US2009053204, 2009.
112. Denlinger LC, Schell K, Angelini G, et al. A novel assay to detect nucleotide receptor P2X7 genetic polymorphisms influencing numerous innate immune functions. J Endotoxin Res 2004; 10: 137-142.
113. Denlinger LC, Angelini G, Schell K, et al. Detection of human P2X7 nucleotide receptor polymorphisms by a novel monocyte pore assay predictive of alterations in lipopolysaccharide-induced cytokine production. J Immunol 2005; 174: 4424-4431.
114. Denlinger LC, Coursin DB, Schell K, et al. Human P2X7 pore function predicts allele linkage disequilibrium. Clin Chem 2006; 52: 995-1004.
115. Denlinger LC, Shi L, Guadarrama A, et al. Attenuated P2X7 pore function as a risk factor for virus-induced loss of asthma control. Am J Respir Crit Care Med 2009; 179: 265-270.
116. Barden JA, Gidley-Baird A. Anti-P2X7 peptides and epitopes. WO2010000041, 2010.
117. Barden JA, Gidley-Baird A. Novel P2X7 epitopes. WO2009033233, 2009.
118. Barden JA, Gidley-Baird A. Hybridomas producing antibodies against non functional P2X7 receptor. WO2008043145, 2008.
119. Gidley-Baird AB, Bardon JA. Antibodies against non-functional P2X7 receptor. WO2008043146, 2008.
120. Barden JA, Gidley-Baird A. Antibodies to non-functional P2X7 receptor. US7326415, 2008.
121. Gidley-Baird A, Barden JA. Antibodies to non-functional P2X7 receptor diagnosis and treatment of cancers and other conditions. WO2002057306, 2002.
122. Barden JA, Sluyter R, Gu BJ, Wiley JS. Specific detection of nonfunctional human P2X7 receptors in HEK293 cells and B- lymphocytes. FEBS Lett 2003; 538: 159-162.
123. Worthington RA, Smart ML, Gu BJ, et al. Point mutations confer loss of ATP-induced human P2X7 receptor function. FEBS Lett 2002; 512: 43-46.
124. Slater M, Danieletto S, Gidley-Baird A, Teh LC, Barden JA. Early prostate cancer detected using expression of non-functional cytolytic P2X7 receptors. Histopathology 2004; 44: 206-215.
125. Slater M, Danieletto S, Pooley M, Cheng Teh L, Gidley-Baird A, Barden JA. Differentiation between cancerous and normal hyperplastic lobules in breast lesions. Breast Cancer Res Treat 2004; 83: 1-10.
126. Slater M, Scolyer RA, Gidley-Baird A, Thompson JF, Barden JA. Increased expression of apoptotic markers in melanoma. Melanoma Res 2003; 13: 137-145.
127. Gorodeski G, Feng Y-H, Li X. Truncated proteins as cancer mark-ers. US7767789, 2010.
128. Franco DL, Ramanathan CS, Lewis MA, Feder JN. Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v. WO2004090097, 2004.
129. Bader AG, Byrom M, Johnson CD, Brown D. Mir-143 regulated genes and pathways as targets for therapeutic intervention. US20090232893, 2009.
130. Bader AG, Patrawala L, Wiggins JF, Byrom MW, Johnson CD, Brown D. Mir-34 regulated genes and pathways as targets for therapeutic intervention. US20090227533, 2009.
131. Byrom M, Patrawala L, Johnson CD, Brown D, Bader AG. Mir-16 regulated genes and pathways as targets for therapeutic interven-tion. US20090175827, 2009.
132. Bader AG, Byrom M, Johnson CD, Brown D. Mir-20 regulated genes and pathways as targets for therapeutic intervention. US20090163434, 2009.
133. Gorodeski G, Potashkin J, Cheatham B. Screening, diagnosing, treating and prognosis of pathophysiologic status by RNA regulation. WO2008115387, 2008.
134. Jimenez AI, Sesto A, Roman JP, et al. Methods and compositions to inhibit P2X7 receptor expression. WO2006024880, 2006.
135. Chu YX, hang Y, Zhang YQ, Zhao ZQ. Involvement of microglial P2X7 receptors and downstream signaling pathways in longterm potentiation of spinal nociceptive responses. Brain Behav Immun 2010; 24: 1176-1189.
136. Lucas JJ, Miras-Portugal MT, Diaz-Hernandez M. Method for the invitrodiagnosis/prognosisofHuntington'schorea. WO2008142194, 2008.
137. Diaz-Hernandez M, Diez-Zaera M, Sanchez-Nogueiro J, et al. Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist admini-stration. FASEB J 2009; 23: 1893-1906.
138. Adriouch S, Bannas P, Schwarz N, et al. ADP-ribosylation at R125 gates the P2X7 ion channel by presenting a covalent ligand to its nucleotide binding site. FASEB J 2008; 22: 861-869.
139. Fuller SJ, Stokes L, Skarratt KK, Gu BJ, Wiley JS. Genetics of the P2X7 receptor and human disease. Purinergic Signal 2009; 5: 257-262.
140. Sluyter R, Shemon AN, Barden JA, Wiley JS. Extracellular ATP increases cation fluxes in human erythrocytes by activation of the P2X7 receptor. J Biol Chem 2004; 279: 44749-4455.
141. Sluyter R, Dalitz JG, Wiley JS. P2X7 receptor polymorphism im-pairs extracellular adenosine 5'-triphosphate-induced interleukin-18 release from human monocytes. Genes Immunity 2004; 5: 588-591.
142. Sluyter R, Shemon AN, Wiley JS. P2X7 receptor activation causes phosphatidylserine exposure in human erythrocytes. Biochem Bio-phys Res Commun 2007; 355: 169-173.
143. Shemon AN, Sluyter R, Wiley JS. Rottlerin inhibits P2X7 receptor stimulated phospholipase D activity in chronic lymphocytic leu-kaemia B-lymphocytes. Immunol Cell Biol 2007; 85: 68-72.
144. Gartland A, Skarratt KK, Hocking LJ, et al. Loss of function poly-morphisms in the P2X7 receptor gene are associated with accelerated lumbar spine bone loss in postmenopausal women. J Bone Mineral Res 2008; 23: S296.
145. Ohlendorff SD, Tofteng CL, Jensen JEB, et al. Single nucleotide polymorphisms in the P2X7 gene are associated to fracture risk and to effect of estrogen treatment. Pharmacogenet Genomics 2007; 17: 555-567.
146. Nissen N, Madsen JS, Bladbjerg EM, et al. No association between hip geometry and four common polymorphisms associated with fracture: The Danish osteoporosis prevention study. Calcif Tissue Int 2009; 84: 276-285.
147. Mrazek F, Gallo J, Stahelova A, Petrek M. Functional variants of the P2RX7 gene, aseptic osteolysis, and revision of the total hip arthroplasty: A preliminary study. Hum Immunol 2010; 71: 201-205.
148. Lee KH, Sung SP, Kim I, et al. P2X7 receptor polymorphism and clinical outcomes in HLA-matched sibling allogeneic hema-topoietic stem cell transplantation. Haematologica 2007; 92: 651-657.
149. Jamieson SE, Peixoto-Rangel AL, Hargrave AC, et al. Evidence for associations between the purinergic receptor P2X7 (P2RX7) and toxoplasmosis. Genes Immunity 2010; 11: 374-383.
150. Sambasivan V, Murthy KJR, Reddy R, Vijayalakshimi V, Hasan Q. P2X7 gene polymorphisms and risk assessment for pulmonary tu-berculosis in Asian Indians. Dis Markers 2010; 28: 43-48.
151. Xiao J, Sun L, Jiao W, et al. Lack of association between polymor-phisms in the P2X7 gene and tuberculosis in a Chinese Han population. FEMS Immunol Med Microbiol 2009; 55: 107-111.
152. Taype CA, Shamsuzzaman S, Accinelli RA, Espinoza JR, Shaw MA. Genetic susceptibility to different clinical forms of tuberculo-sis in the Peruvian population. Infect Genet Evol 2010; 10: 495-504.
153. Nino-Moreno P, Portales-Perez D, Hernandez-Castro B, et al. P2X7 and NRAMP1/SLC11 A1 gene polymorphisms in Mexican mestizo patients with pulmonary tuberculosis. Clin Exp Immunol 2007; 148: 469-477.
154. Mokrousov I, Sapozhnikova N, Narvskaya O. Mycobacterium tuberculosis co-existence with humans: Making an imprint on the macrophage P2X7 receptor gene? J Med Microbiol 2008; 57: 581-584.
155. Tekin D, Kayaalti Z, Dalgic N, et al. Polymorphism in the P2X7 gene increases susceptibility to extrapulmonary tuberculosis in Turkish children. Pediatr Infect Dis J 2010; 29: 779-782.
156. Sharma S, Kumar V, Khosla R, Kajal N, Sarin B, Sehajpal PK. Association of P2X7 receptor +1513 (A>C) polymorphism with tuberculosis in a Punjabi population. Int J Tuberc Lung Dis 2010; 14: 1159-1163.
157. Palomino-Doza J, Rahman TJ, Avery PJ, et al. Ambulatory blood pressure is associated with polymorphic variation in P2X receptor genes. Hypertension 2008; 52: 980-985.
158. Haas SL, Ruether A, Singer MV, Schreiber S, Bocker U. Func-tional P2X7 receptor polymorphisms (His155Tyr, Arg307Gln, Glu496Ala) in patients with Crohn's disease. Scand J Immunol 2007; 65: 166-170.
159. Eslick GD, Thampan BV, Nalos M, McLean AS, Sluyter R. Circu-lating interleukin-18 concentrations and a loss-of-function P2X7 polymorphism in heart failure. Int J Cardiol 2009; 137: 81-83.
160. Portales-Cervantes L, Nino-Moreno P, Doni-z-Padilla L, et al. Expression and function of the P2X7 purinergic receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. Hum Immunol 2010; 71: 818-825.
161. Lester S, Skarratt K, Gu B, Downie-Doyle S, Wiley J, Rischmuel-ler M. Functional polymorphisms of the P2X7 gene influence susceptibility to Ro/la autoantibody-positive primary Sjogren's syn-drome. Arthritis Rheumatism 2008; 58: S792.
162. Forchap SL, Anandacoomarasamy A, Wicks J, et al. P2X7 gene polymorphisms do not appear to be a susceptibility gene locus in sporadic cases of systemic lupus erythematosus. Tissue Antigens 2008; 72: 487-490.
163. Dao-Ung LP, Fuller SJ, Sluyter R, et al. Association of the 1513C polymorphism in the P2X7 gene with familial forms of chronic lymphocytic leukaemia. Br J Haematol 2004; 125: 815-817.
164. Paneesha S, Starczynski J, Pepper C, et al. The P2X7 receptor gene polymorphism 1513A>C has no effect on clinical prognostic markers and survival in multiple myeloma. Leukemia Lymphoma 2006; 47: 281-284.
165. Jalbout M, Bouaouina N, Chouchane L. Genetic variation in the P2X7 apoptosis purinoreceptor correlated with anti-nuclear and cytoskeleton autoantibodies induction in nasopharyngeal carcinoma Cancer Ther 2004; 2: 463-468.
166. Dardano A, Falzoni S, Caraccio N, et al. 1513A>C polymorphism in the P2X7 receptor gene in patients with papillary thyroid cancer: Correlation with histological variants and clinical parameters. J Clin Endocrinol Metab 2009; 94: 695-698.
167. Erhardt A, Lucae S, Unschuld PG, et al. Association of polymor-phisms in P2RX7 and CaMKKb with anxiety disorders. J Affect Disord 2007; 101: 159-168.
168. Hansen T, Jakobsen KD, Fenger M, et al. Variation in the puriner-gic P2RX7 receptor gene and schizophrenia. Schizophrenia Res 2008; 104: 146-152.